Why CervoMed Inc.’s (CRVO) Stock Is Down 7.75%
As of Friday, July 10, CervoMed Inc.’s CRVO share price has dipped by 7.75%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why CervoMed Inc.’s (CRVO) Stock Is Down 5.55%
As of Tuesday, January 27, CervoMed Inc.’s CRVO share price has dipped by 5.55%, which has investors questioning if this is right time to buy.Jenna Brashear
Why CervoMed Inc.’s (CRVO) Stock Is Down 5.89%
As of Monday, January 26, CervoMed Inc.’s CRVO share price has dipped by 5.89%, which has investors questioning if this is right time to buy.Jenna Brashear
Why CervoMed Inc.’s (CRVO) Stock Is Down 5.85%
As of Friday, January 23, CervoMed Inc.’s CRVO share price has dipped by 5.85%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why CervoMed Inc.’s (CRVO) Stock Is Down 6.01%
As of Wednesday, January 21, CervoMed Inc.’s CRVO share price has dipped by 6.01%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | CRVO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $33.9 | $208.8 | 13% |
|
| Shares Out (Mil) | 10.2 | 53.9 | 21% |
|
| Institutional Ownership | 30.9% | 93.1% | 13% |
|
| Float (Mil) | 9.6 | 41.4 | 19% |
|
| Beta | -4.31 | 0.95 | 0% |
|
| Avg Daily Volume (000s) | 423 | 614 | 55% |
|
| Price Change (52-week) |
(72.4%) | 45.3% | 12% |
|
| Growth | CRVO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | na | (10.2%) | na |
|
| EPS (5yr) | na | 15.7% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 4 | |
| Current EPS | ($0.500) | ($2.132) | ($1.385) | |
| Month Ago EPS | ($0.568) | ($2.202) | ($1.475) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.585) | ($2.665) | ($2.318) | |
| Year/Year Chg | (22.0%) | (28.5%) | (72.2%) | |
| Financials | CRVO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $37 | 1% |
|
| Net Income (TTM) (Mil) | ($30) | ($44) | 21% |
|
| EPS (TTM) | ($3.193) | ($1.600) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($28) | ($33) | 13% |
|
| Net Cash Flow (TTM) (Mil) | $14 | $2 | 59% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $13 | $174 | 9% |
|
| Valuation | CRVO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.32 | 2.09 | 37% |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CRVO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (94.7%) | (47.2%) | 6% |
|
| ROE | (107.6%) | (54.2%) | 8% |
|
| Liabilities to Assets | 11.7% | 29.1% | 7% |
|
| F-Score | 2 | 2 | 7% |
|
CervoMed Inc. did not pass any screens on 10/16/2026.
